NILE Study Results Demonstrating Guardant360’s High Concordance to Tissue Testing in Advanced NSCLC Published in Clinical Cancer Research

Ads

You May Also Like

Taiwan Liposome Company Reports Positive Top-Line Data from Phase II Clinical Trial of TLC599 in Knee Osteoarthritis Pain

Primary endpoint and key secondary endpoints metTLC599 demonstrated statistically significant improvement over placebo through  ...

Aquinox Announces Appointment of Dr. Kelvin Neu and Dr. Richard Levy to Board of Directors

VANCOUVER, British Columbia, March 27, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), ...